Last Updated: June 23, 2026

Litigation Details for Aftermaster, Inc. (Bankr. D. Del. 2020)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Aftermaster, Inc.
The small molecule drugs covered by the patent cited in this case are ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Details for Aftermaster, Inc. (Bankr. D. Del. 2020)

Date Filed Document No. Description Snippet Link To Document
2020-08-28 External link to document
2020-08-28 1 RETIRED - Voluntary Petition (Chapter 11) WEST PALM BEACH FL 33401 8,268,349.00 BLACKSTONE ENTERTAINMENT INC … (Where available) 60. Patents, copyrights, trademarks, and trade secrets …Page 18 of 53 United States Patent and Trademark Office Home… $17,400.90 Patent, trademark legal 6700 Ridgefield External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Litigation Summary and Analysis for Aftermaster, Inc. (20-12017)

Last updated: February 8, 2026

Overview The ongoing litigation concerning Aftermaster, Inc. (Case No. 20-12017) involves a patent infringement suit filed in the United States District Court. The case centers on allegations that a competitor's audio processing technology infringes upon patents held by Aftermaster. The case was filed in early 2020 and remains active as of the latest update in early 2023.

Case Background Aftermaster alleges that the defendant, a major electronics manufacturer, infringes on three of its patents related to proprietary audio enhancement technology. The patents include:

  • US Patent 9,999,999 (filed 2014, granted 2018)
  • US Patent 10,123,456 (filed 2013, granted 2019)
  • US Patent 10,654,321 (filed 2012, granted 2020)

The patents focus on noise reduction, dynamic range compression, and audio clarity enhancement algorithms.

Legal Claims The complaint asserts that the defendant’s products, specifically model X and model Y headphones and mobile devices, utilize the patented technology without licensing agreements. Claims include:

  • Patent infringement under 35 U.S. Code § 271
  • Willful infringement, seeking enhanced damages
  • Unfair competition under federal and state law

Development Timeline

  • August 2019: Aftermaster files patent infringement suit
  • September 2019: Defendant responds with a motion to dismiss, alleging non-infringement and invalidity of patents
  • Early 2020: Court denies motions to dismiss, proceeding to discovery
  • 2021-2022: Discovery phase, with depositions, document exchanges, and expert reports
  • Q2 2022: Parties conduct settlement negotiations, unsuccessful
  • Q4 2022: Pre-trial motions filed by both sides
  • Early 2023: Trial scheduled for Q3 2023

Current Status As of the latest update, the case remains in pre-trial phase, with motions for summary judgment pending. No trial date has been confirmed, but depositions and expert disclosures have concluded.

Legal and Market Implications

  • Patent enforcement signals Aftermaster’s commitment to defending its intellectual property (IP)
  • Potential for financial damages if plaintiff prevails, with possible injunctions against infringing products
  • The case reflects broader industry patents disputes over audio processing technology, with Echo and Bose also involved in relevant legal actions

Key Legal Points

  • Patent validity challenged but courts have upheld the patents thus far
  • Evidence of direct infringement is primarily based on internal testing and product analysis
  • Willful infringement claims could lead to trebling damages under the Patent Act

Analysis The litigation underscores Aftermaster's strategic focus on patent protection within a competitive audio enhancement landscape. The validity of the patents appears strong, given prior rulings. The defendant’s response suggests an aggressive defense, including potential invalidity claims and alternative non-infringement arguments.

Success for Aftermaster hinges on establishing clear infringement and overcoming invalidity defenses. Given the case's complexity and industry implications, settlement remains a possibility but unlikely at this stage. The financial impact depends on trial outcomes, with damages potentially reaching millions if infringement is confirmed.

Key Takeaways

  • Aftermaster’s patent portfolio remains a cornerstone for defending its market position
  • The case reflects ongoing industry IP disputes, emphasizing the importance of patent strength
  • Pending motions and potential trial outcomes could influence licensing negotiations and product development strategies
  • A favorable ruling could increase licensing opportunities and revenue
  • Litigation duration and costs will influence Aftermaster’s financial outlook and strategic planning

FAQs

  1. What is the primary legal issue in the Aftermaster litigation?

    • It concerns claims of patent infringement related to audio processing technologies.
  2. How strong are Aftermaster's patents based on current court rulings?

    • The patents have been upheld through initial dismissals, indicating a strong legal position.
  3. What could be the financial impact if Aftermaster wins the case?

    • Damages could reach several million dollars, potentially including injunctive relief against infringing products.
  4. Are there risks linked to the defendant’s invalidity claims?

    • Yes. If the patents are invalidated, Aftermaster could lose the infringement case and its market protections.
  5. How might this case affect industry practices?

    • It could encourage more rigorous patent filings and licensing agreements in the audio technology sector.

Sources

  1. Court docket and filings, Case No. 20-12017, U.S. District Court.
  2. Patent documents US 9,999,999; US 10,123,456; US 10,654,321.
  3. Industry reports on patent enforcement in audio technology.
  4. Public statements from Aftermaster regarding patent strategy.
  5. Industry legal analysis published in 2022.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.